Skip to main content

Table 3 Associations between TDP-43 and cerebrovascular disease pathologies using binary logistic regression (n = 929)

From: Dichotomous scoring of TDP-43 proteinopathy from specific brain regions in 27 academic research centers: associations with Alzheimer’s disease and cerebrovascular disease pathologies

Region Model 1a Model 2b
OR (95% CI) P-value OR (95% CI) P-value
Atherosclerosis of the circle of Willis (moderate + severe vs. none + mild)
 Amygdala 0.96 (0.63–1.47) 0.87 0.90 (0.58–1.39) 0.63
 Hippocampus 1.07 (0.74–1.55) 0.70 0.98 (0.67–1.43) 0.93
 EC/inferior TCTX 1.16 (0.77–1.75) 0.48 1.07 (0.70–1.62) 0.77
 Frontal neocortex 1.03 (0.47–2.27) 0.93 1.00 (0.45–2.21) 0.99
Cerebral amyloid angiopathy (moderate + severe vs. none + mild)
 Amygdala 0.82 (0.52–1.28) 0.38 0.66 (0.41–1.04) 0.077
 Hippocampus 0.89 (0.59–1.32) 0.57 0.71 (0.47–1.07) 0.10
 EC/inferior TCTX 0.99 (0.64–1.52) 0.97 0.79 (0.50–1.22) 0.29
 Frontal neocortex 1.16 (0.49–2.60) 0.73 1.11 (0.46–2.56) 0.81
Infarct and lacunes (yes vs. no)
 Amygdala 0.77 (0.43–1.32) 0.35 0.84 (0.47–1.45) 0.54
 Hippocampus 0.76 (0.45–1.23) 0.28 0.81 (0.48–1.33) 0.42
 EC/inferior TCTX 0.79 (0.45–1.32) 0.38 0.87 (0.49–1.48) 0.61
 Frontal neocortex 1.64 (0.63–3.82) 0.27 1.66 (0.63–3.89) 0.26
Microinfarcts (yes vs. no)
 Amygdala 1.15 (0.73–1.79) 0.55 1.08 (0.68–1.70) 0.74
 Hippocampus 1.14 (0.76–1.70) 0.51 1.14 (0.75–1.70) 0.54
 EC/inferior TCTX 1.25 (0.80–1.94) 0.31 1.21 (0.77–1.88) 0.41
 Frontal neocortex 1.76 (0.78–3.84) 0.16 1.77 (0.78–3.86) 0.16
Hemorrhages and microbleeds (yes vs. no)
 Amygdala 0.65 (0.26–1.44) 0.32 0.65 (0.25–1.47) 0.33
 Hippocampus 0.71 (0.30–1.50) 0.40 0.69 (0.29–1.46) 0.36
 EC/inferior TCTX 0.57 (0.21–1.29) 0.21 0.55 (0.20–1.26) 0.19
 Frontal neocortex 0.45 (0.02–2.34) 0.45 0.44 (0.02–2.32) 0.44
Arteriolosclerosis (moderate + severe vs. none + mild)
 Amygdala 1.56 (1.03–2.37) 0.038 1.38 (0.90–2.13) 0.14
 Hippocampus 1.31 (0.92–1.89) 0.14 1.16 (0.80–1.69) 0.42
 EC/inferior TCTX 1.77 (1.17–2.72) 0.0078 1.61 (1.05–2.49) 0.029
 Frontal neocortex 0.97 (0.45–2.13) 0.95 0.93 (0.43–2.06) 0.86
  1. aOdds ratios were adjusted for sex, age at death, APOE genotype, and the type of TDP-43 antibody used
  2. bThal Aβ phase and Braak NFT stage were included as additional covariates in model 2
  3. OR odds ratio, CI confidence interval, EC entorhinal cortex, TCTX temporal cortex
  4. Bold p-value represents the statistical significance